To review the pharmacologic properties of and uses for the most commonly prescribed antiviral agents.
Data Sources:
A MEDLINE/PubMed search (1966–September 2010) was conducted for English-language articles using the terms HIV, hepatitis, cytomegalovirus (CMV), herpes simplex virus (HSV), antiviral agents, antiretroviral agent, acyclovir, valganciclovir, valacyclovir, interferon, ribavirin, ritonavir, efavirenz, zidovudine, darunavir, lopinavir, tenofovir, raltegravir, lamivudine, atazanavir, and emtricitabine. Book chapters and recent guidelines pertaining to the pathophysiology or pharmacologic properties of antiviral agents were also reviewed.
Study Selection and Data Extraction:
Articles, chapters, and guidelines pertaining to the relevant pharmacologic agents were collected for review.
Data Synthesis:
Viral pathogens affect multiple organs, causing direct and indirect damage by activating an immune response. Unlike bacterial infections, which can be eradicated from the host system, viral infections are not curable. Antiviral treatments are prescribed to reduce morbidity and mortality. There are many antiviral and more than 20 antiretroviral agents currently approved by the FDA. These include acyclovir, valacyclovir, and famciclovir for HSV; ganciclovir, valganciclovir, foscarnet, and cidofovir for CMV; interferon and ribavirin for hepatitis; efavirenz, tenofovir, emtricitabine, atazanavir, darunavir, lopinavir, ritonavir, raltegravir, zidovudine, and lamivudine as first-line agents for HIV.
Conclusions:
Viral illnesses affect a large portion of the population. Given the multitude of drugs available, pharmacists and pharmacy technicians should be educated about common treatment options. Having a strong knowledge of commonly prescribed antiviral drugs allows these frontline professionals to make a significant impact on the quality of care that they provide to their patients and community.
Get full access to this article
View all access options for this article.
References
1.
ChapellJDermodyT. Introduction to viruses and viral diseases. In: Mandell, Douglas, and Bennett's principles and practice of infectious diseases, 7th ed.Burlington, MA: Churchill Livingstone, an imprint of Elsevier, 2009;1902–21 (accessed 2010 Apr 10).
2.
CrumpackerCIIZhangJ. Cytomegalovirus. In: Mandell, Douglas, and Bennett's principles and practice of infectious diseases, 7th ed.Burlington, MA: Churchill Livingstone, an imprint of Elsevier, 2009;1971–87 (accessed 2010 Apr 12).
Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. MMWR2006; 55: 1–100.
6.
Package insert. Zovirax (acyclovir cream). Triangle Park, NC: GlaxoSmithKline, October 2008.
7.
Package insert. Zovirax (acyclovir ointment). Triangle Park, NC: GlaxoSmithKline, October 2008.
8.
AokiFYHaydenFGDolinR. Antiviral drugs (other than antiretrovirals). In: Mandell, Douglas, and Bennett's principles and practice of infectious diseases, 7th ed.Burlington, MA: Churchill Livingstone, an imprint of Elsevier, 2009;565–610. (accessed 2010 Apr 30).
9.
FeinbergJEHurwitzSCooperD. A randomized, double-blind trial of valganciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. J Infect Dis1998; 177: 48–56.
10.
Package insert. Zovirax (acyclovir). Triangle Park, NC: GlaxoSmithKline, June 2005.
11.
Package insert. Zovirax (acyclovir sodium for injection). Triangle Park, NC: GlaxoSmithKline, November 2003.
12.
Package insert. Famvir (famciclovir tablets). East Hanover, NJ: Novartis, December 2009.
13.
ShawFEDavisSFRutledgeTF. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep2009; 58: 1–207.
14.
BironKKStanatSCSorrellJB. Metabolic activation of the nucleoside analog 9{[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl} guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci U S A1985; 85: 2473–7.
15.
SullivaVTalaricoCLStanatSCDavisMCoenDMBironKK. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature1992; 358: 162–4.
16.
LittlerEStuartADCheeMS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature1992; 358: 160–2
17.
AndersonRDGriffyKGJungDDorrAHulseJDSmithRB. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus and cytomegalovirus-seropositive patients. Clin Ther1995; 17: 425–32.
18.
Goodman and Gilman's the pharmacological basis of therapeutics. 11th ed.New York: McGraw-Hill Companies, Inc., 2006. (accessed 2010 Aug 5).
19.
Package insert. Valtrex (valacyclovir hydrochloride). Triangle Park, NC: GlaxoSmithKline, September 2008.
20.
GhanyMGStraderDBThomasDLSeeffLB. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology2009; 4: 1335–74.
21.
National Center for Immunization and Respiratory Diseases, Division of Viral Diseases. CDC Web site for CMV (updated March 12, 2010). http://www.cdc.gov/hepatitis. (accessed 2010 Apr 20).
22.
Package insert. Copegus (ribavirin). South San Francisco, CA: Hoffmann-LaRoche Inc, June 2010.
23.
Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2009;1–161. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. (accessed 2010 Oct 10).
24.
ThompsonMAAbergJACahnP. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA Panel. JAMA2010; 304: 321–33.
25.
PatersonDLSwindellsSMohrJ. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med2000; 133: 21–30.
Package insert. Ziagen (abacavir). Research Triangle Park, NC: GlaxoSmithKline, January 2009.
28.
WesterCWOkezieOAThomasAM. Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: Preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr2007; 46: 318–22.
29.
HaubrichRHRiddlerSADiRienzoAG. Metabolic outcomes in a randomized trial of nucleoside, non nucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS2009; 23: 1109–18.
30.
Package insert. Epivir (lamivudine). Research Triangle Park, NC: GlaxoSmithKline, October 2007.
31.
Package insert. Tenofovir (viread). Foster City, CA: Gilead Sciences Inc., March 2010.
Package insert. Emtriva (emtricitabine)Foster City, CA: Gilead Sciences, Inc., May 2008.
34.
NüeschRAnanworanichJSrasuebkulP. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. AIDS2008; 22: 152–4.
35.
PhillipsEJSullivanJRKnowlesSR. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS2002; 16: 2223–5.
36.
D.A.D. Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med2007; 356: 1723–35.
37.
IoannidisJPAAbramsEJAmmannA. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/mL. J Infect Dis2001; 183: 539–45.
38.
MofensonLMLambertJSStiehmER. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Engl J Med1999; 341: 385–93.
39.
GarciaPMKalishLAPittJ. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med1999; 341: 394–402.
40.
Package insert. Retrovir (zidovudine). Triangle Park, NC: GlaxoSmithKline, 2009.
41.
CampbellTSmeatonLDe GrutllaV. PEARLS (ACTG A5175): a multinational study of didanosine-EC, emtricitabine and atazanavir vs co-formulated zidovudine/lamivudine and efavirenz for initial treatment of HIV-1 infection (abstract THAB0404). 17th International AIDS Conference. Mexico City, August 3–8, 2008.
CassettiIMadrugaJVEtzelA. The safety and efficacy of tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral-naïve patients through seven years (abstract TUPE0057). 17th International AIDS Conference. Mexico City, August 3–8, 2008.
BrownTTMcComseyGAKingMS. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr2009; 51: 554–61.
46.
KarrasALafaurieMFurcoA. Tenofovir related nephrotoxicity in human immunodeficiency virus-infected patients: Three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis2003; 36: 1070–3.
47.
MaggioloF. Efavirenz: A decade of clinical experience in the treatment of HIV. J Antimicrob Chemother2009; 64: 910–28.
48.
FordNMofensonLKranzerK. Safety of efavirenz in firsttrimester of pregnancy: A systematic review and meta-analysis of outcomes from observational cohorts. AIDS2010; 24: 1461–70.
49.
Package insert. Viramune (nevirapine). Ridgefield, CT: Boehringer Ingelheim, June 2010.
50.
Package insert. Intelence (etravirine). Raritan, NJ: Tibotec, Inc., July 2010.
CareyDAminJBoydM. Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: Systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother2010; 65: 1878–88.
55.
CroomKFDhillionSKeamSJ. Atazanavir: A review of its use in the management of HIV-1 infection. Drugs2009; 69: 1107–40.
56.
ClotetBBellosNMolinaJM. Efficacy and safety of darunavir-ritonavir at Hjek 48 in treatment-experienced patients with HIV-1 infection. POWER 1 and 2: Pooled subgroup analysis of data from two randomized controlled trials. Lancet2007; 369: 1169–78.
57.
DeMeyerSMSpinosa-GuzmanSVangeneugdenTJ. Efficacy of once-daily darunavir/ritonavir 800 mg/100 mg in HIV-infected treatment experienced patients with no baseline resistance-associated mutations to darunavir. J Acquir Immune Defic Syndr2008; 49: 179–82.
58.
McKeageKPerryCMKeamSJ. Darunavir: A review of its use in the management of HIV infection. Drugs2009; 69: 477–503.
59.
Package insert. Lexiva (fosamprenavir). Research Triangle Park, NC: GlaxoSmithKline, April 2010.
